Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine and/or Lactobacillus casei DG for maintenance of remission in symptomatic uncomplicated diverticular disease
2006-006322-26Phase 3Completed
- Sponsor
- Policlinico Gemelli
- Start
- Apr 2007
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine and lactobacillus casei DG in diverticular disease and Symptomatic uncomplicated diverticular disease (SUDD) (4 arms), sponsored by Policlinico Gemelli. Primary endpoint: Remission of diverticular disease. Started Apr 2007; status: completed.
02
Drugs
Salcrozinelactobacillus casei DG
03
Conditions
diverticular diseaseSymptomatic uncomplicated diverticular disease (SUDD)
Beyond the preview
Go deeper on 2006-006322-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006322-26.